BayMark operates outpatient Suboxone® programs across the United States. Sometimes referred to as office-based opioid treatment (OBOT) programs, OBOTs offer a different level of care than a structured opioid treatment program (OTP), operating similarly to a physician’s office. Medication-assisted treatment and in-house professional counseling form the basis of an OBOT program with more flexible scheduling available.
OBOTs utilize buprenorphine and buprenorphine compounds, approved by the FDA in the early 2000’s for the treatment of opioid addiction. Unlike methadone, which can only be dispensed through a structured OTP, buprenorphine is prescribed by a physician and filled through the patient’s preferred pharmacy. The ability to obtain the medication through a pharmacy allows patients to visit the treatment facility less frequently.
Buprenorphine is available as an individual medication or as part of a combination product containing buprenorphine and naloxone. These combination products are known as Suboxone®, Bunavail® or Zubsolv®, with the most commonly prescribed medication being Suboxone®. The combination of buprenorphine and naloxone offers several advantages including: